- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01931085
Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)
April 29, 2021 updated by: University of Colorado, Denver
"Compassionate Use of Triclabendazole for the Treatment of Parasites" (Prior to FDA Approval; Expanded Access Program)
Triclabendazole is a benzimidazole compound used as a systemic antihelmintic in veterinary practice.
Triclabendazole is considered to be a second-line drug for parasites and is used when other preferred agents cannot be used because they are ineffective or because adverse reactions limit their use.
Although Triclabendazole is widely used in developing countries for the treatment of parasites it is not approved by the FDA for this treatment in the US.
It is currently being distributed in the US through a special arrangement with the FDA and the manufacturer on an individual patient approval basis.
This arrangement requires that a single patient Investigational New Drug (IND) be obtained from FDA for each patient requiring Triclabendazole.
Upon approval by FDA, the manufacturer (Novartis) will ship the drug directly to the prescribing physician.
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 97 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a diagnosis of parasites whose resistance pattern has indicated resistance to first line agents and sensitivity to Triclabendazole or in whom an additional drug needs to be added to their regimen because of inadequate response to existing therapy.
- Patients with a parasite that is sensitive to Triclabendazole and who have experienced an allergic or adverse reaction to other agents that prevent their use.
- Patients with parasitic disease that has responded to treatment with first line drugs but who experienced allergic or adverse reactions to these agents that has prevented their continued use or who have experienced a relapse in their disease that necessitates the addition, or substitution, of second-line agents
- Patients who do not qualify for a study using Triclabendazole or for whom a study does not exist and thus the patient would not otherwise have access to the drug
Exclusion Criteria:
- Anyone whose parasitic disease can be adequately treated by other available medications.
- Anyone who is allergic or who has had a severe adverse reaction to Triclabendazole in the past.
- Pregnant Women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marilyn Levi, MD, University of Colorado, Denver
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
August 22, 2013
First Submitted That Met QC Criteria
August 22, 2013
First Posted (Estimate)
August 29, 2013
Study Record Updates
Last Update Posted (Actual)
May 4, 2021
Last Update Submitted That Met QC Criteria
April 29, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-1438
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parasitic Disease
-
Nicolaus Copernicus UniversityCompletedChronic Disease | Intestinal Disease, ParasiticPoland
-
Al-Azhar UniversityCompleted
-
Sohag UniversityNot yet recruitingIntestinal Parasitic Infection
-
National Institute of Allergy and Infectious Diseases...TerminatedCryptosporidiosis | Amebiasis | Parasitic Disease | Giardiasis | Parasitic Intestinal Disease | Gastrointestinal Helminth InfectionsUnited States
-
Region StockholmRecruitingMalaria | Parasitic InfectionSweden
-
University of MalayaCompletedKnowledge, Attitudes, Practice | Intestinal Parasitic InfectionsMalaysia
-
Sohag UniversityRecruitingIrritable Bowel SyndromeEgypt
-
Mekelle UniversityUniversity of Alcala; Maastricht UniversityCompletedAnaemia | Intestinal Parasitic InfectionsEthiopia
-
Sana'a UniversityUniversity of Malaya; Ministry of Health, MalaysiaCompletedAnemia | Malnutrition | Intestinal Parasitic InfectionsMalaysia
-
University of OxfordRecruitingInfections | Vector Borne Diseases | Malaria | Malaria,Falciparum | Parasitic DiseaseUnited Kingdom
Clinical Trials on Triclabendazole
-
Novartis PharmaceuticalsRecruitingFascioliasisVietnam, Egypt, Colombia, Peru
-
Universidad Peruana Cayetano HerediaNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting